成人复发或难治性皮肤型IgA血管炎的治疗策略与结局:多中心回顾性队列研究
结果显示单用氨苯砜3个月皮肤缓解率82%,单用糖皮质激素或联合秋水仙碱/氨苯砜为73%,cDMARDs为71%,秋水仙碱为57%。
要点
- 单用氨苯砜3个月皮肤缓解率为82%,复发率46%。
- 糖皮质激素单用或联合方案3个月皮肤缓解率73%,复发率23%。
- cDMARDs 3个月皮肤缓解率71%、复发率29%;秋水仙碱分别为57%和7%。
核心结论
- 在成人复发或难治性皮肤型IgA血管炎中,氨苯砜、糖皮质激素和cDMARDs提供了最高的皮肤缓解率。
- 考虑到风险获益比和潜在不良事件,氨苯砜似乎是成人复发或难治性皮肤型IgA血管炎的一个有趣选择。
研究设计与样本
- 主要终点为第3个月时的皮肤缓解率。
主要发现
- 一线治疗为秋水仙碱者占54%,低剂量糖皮质激素(GCs)者占38%。
- 一线治疗失败后,患者接受中位1[1-2.3]线额外治疗。
- 第3个月皮肤缓解率:单用氨苯砜82%,单用GCs或联合秋水仙碱/氨苯砜73%,cDMARDs 71%,秋水仙碱57%。
- 复发率:单用氨苯砜46%,单用GCs或联合秋水仙碱/氨苯砜23%,cDMARDs 29%,秋水仙碱7%。
临床怎么用
- 在成人复发或难治性皮肤型IgA血管炎中,氨苯砜、GCs和cDMARDs的3个月皮肤缓解率分别为82%、73%和71%。
- 单用氨苯砜的复发率为46%,单用GCs或联合方案为23%,cDMARDs为29%,秋水仙碱为7%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IgA vasculitis is a rare disease in adults, with a relapsing or refractory course in some cases. Non-severe cutaneous relapses have been less documented than those with renal involvement, and data on the therapeutic management of such situations are lacking. We aimed to evaluate the cutaneous response rate with different treatment regimens. METHODS: This French retrospective multicenter study included patients with IgA vasculitis who experienced cutaneous relapses or refractory disease after first-line therapy. The primary endpoint was the rate of cutaneous response at month 3. RESULTS: Fifty-two patients were included, 64% of whom were male. First-line therapy was colchicine in 54% and low-dose glucocorticoids (GCs) in 38%. After failure of the first-line therapy, patients received a median of 1 [1-2.3] additional line of treatment. Cutaneous response at 3 months was achieved in 82% with dapsone alone, 73% with GCs alone or in combination with colchicine or dapsone, 71% with cDMARDs and 57% with colchicine. The relapse rate was 46% with dapsone alone, 23% with GCs alone or in combination with colchicine or dapsone, 29% with cDMARDs and 7% with colchicine. CONCLUSION: In adult relapsing or refractory cutaneous IgA vasculitis, dapsone, GCs and cDMARDs provided the highest rates of cutaneous response. Considering the risk-benefit ratio and potential adverse events, dapsone appears to be an interesting option in adult relapsing or refractory cutaneous IgA vasculitis.
引用
- Glatre A, Mahévas T, Jaccard C, et al. Treatment strategies and outcomes in adult relapsing or refractory cutaneous IgA Vasculitis: A multicenter retrospective cohort study. Semin Arthritis Rheum. 2025. PMID: 41270569. doi:10.1016/j.semarthrit.2025.152870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。